NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

On another note, the five year survival we heard about Tuesday is real survival — not extrapolated. In other words, they did not take a pool strewn across two to six years to arrive at five year survival, instead, they took patient data on all patients initially enrolled through five years. Over 13% survived. It appears all lost to follow up were found.

No, it shows 25 actually lived 5 years. That is only 10.8%. To get to 13% they estimated the survival of the LTFU's, many who had been on study only a year or so before being lost.

The next endpoint concerns OS against a placebo control. The final one is tumor response against a placebo control. Seeing the excellent p values and hazard ratios today on the primary and follow up endpoint, i’m assuming the next four endpoints might be better than some crtitics might assume. Just because they weren’t shared with topline results, does nit mean they are a foregone conclusion

How is the OS between the 232 and 99 be anything other than a complete failure when the blended population lived longer than the treatment arm?

The surprising (I was not expecting this) statistical significance against residual disease...

Think hard of the populations being compared and the inclusion criterion. Will explain in another post.